

Can't fill your Descovy prescription? Learn about FDA-approved alternatives like generic Truvada, Apretude, and Lenacapavir for HIV treatment and PrEP.
If you've been prescribed Descovy but can't find it in stock or afford the cost, you're not out of options. Several FDA-approved alternatives can provide similar protection against HIV — whether you use it for treatment or prevention. In this guide, we'll explain what Descovy is, how it works, and walk you through the best alternatives available in 2026.
Descovy is a brand-name medication made by Gilead Sciences that contains two active ingredients: Emtricitabine (200 mg) and Tenofovir Alafenamide (25 mg), often abbreviated as FTC/TAF. It belongs to a class of drugs called nucleoside reverse transcriptase inhibitors (NRTIs).
Descovy is used for:
Important note: Descovy for PrEP is not approved for individuals at risk from receptive vaginal sex. If that applies to you, talk to your doctor about Truvada or other options instead.
For a deeper dive into the medication, see What Is Descovy? Uses, Dosage, and What You Need to Know.
Descovy works by blocking an enzyme called reverse transcriptase that HIV needs to copy itself inside your body. Both ingredients — Emtricitabine and Tenofovir Alafenamide — interfere with this process at the molecular level, preventing the virus from multiplying.
Tenofovir Alafenamide (TAF) is a newer, more targeted form of tenofovir. It achieves effective antiviral levels at a dose 10 times lower than the older form (tenofovir disoproxil fumarate, or TDF), which means less drug circulating in your bloodstream. This translates to fewer kidney and bone side effects compared to TDF-based medications like Truvada.
For the full explanation, read our article on how Descovy works.
Generic Truvada is the most common alternative to Descovy and is widely available across the United States. It contains Emtricitabine (the same ingredient in Descovy) plus Tenofovir Disoproxil Fumarate (TDF) — an older form of tenofovir.
Key facts about generic Truvada:
For many patients, generic Truvada is an excellent choice — especially if cost or availability is a concern. It's been used for PrEP since 2012 and has a long track record of safety and effectiveness.
Apretude is a long-acting injectable PrEP option made by ViiV Healthcare. Instead of taking a daily pill, you receive an injection from your healthcare provider every 2 months (after two initial monthly doses).
Key facts about Apretude:
Lenacapavir, sold under the brand names Sunlenca (for treatment) and Yeztugo (for PrEP), is the newest option in HIV prevention. Made by Gilead Sciences, it's a twice-yearly injection — meaning you only need to visit your provider every 6 months.
Key facts about Lenacapavir:
The best alternative depends on your individual situation. Here's a quick comparison:
Always talk to your healthcare provider before switching medications. They can evaluate your health history, run appropriate lab tests, and recommend the best option for you. Find a prescriber near you: How to Find a Doctor Who Can Prescribe Descovy Near You.
Not being able to fill your Descovy prescription is frustrating, but it shouldn't stop you from protecting yourself against HIV. Generic Truvada, Apretude, and Lenacapavir are all proven alternatives that may be more accessible or affordable for you in 2026.
If you'd still prefer Descovy, try using Medfinder to check stock at pharmacies near you, or explore savings programs that can bring the cost down. The most important thing is to stay protected — whichever medication you and your doctor choose.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.